Market Overview

CASCADIAN THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout

Share:

Rigrodsky & Long, P.A.:

  • Do you own shares of Cascadian Therapeutics, Inc. (NASDAQ GS: CASC)?
  • Did you purchase any of your shares prior to January 31, 2018?
  • Do you think the proposed buyout is fair?
  • Do you want to discuss your rights?

Rigrodsky
& Long, P.A.
announces that it is investigating potential legal
claims against the board of directors of Cascadian Therapeutics, Inc.
("Cascadian Therapeutics" or the "Company") (NASDAQ GS: CASC)
regarding possible breaches of fiduciary duties and other violations of
law related to the Company's entry into an agreement to be acquired by
Seattle Genetics, Inc. ("Seattle Genetics") (NASDAQ GS: SGEN)
in a transaction valued at approximately $614 million. Under the terms
of the agreement, shareholders of Cascadian Therapeutics will receive
$10.00 in cash for each share of Cascadian Therapeutics common stock.

If you own common stock of Cascadian Therapeutics and purchased any
shares before January 31, 2018, if you would like to learn more about
this investigation, or if you have any questions concerning this
announcement or your rights or interests, please contact Seth D.
Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 300 Delaware
Avenue, Suite 1220, Wilmington, Delaware 19801, by telephone at (888)
969-4242, or by e-mail at info@rl-legal.com.

Rigrodsky
& Long, P.A.
, with offices in Wilmington, Delaware and Garden
City, New York, regularly prosecutes securities
fraud, shareholder corporate, and shareholder derivative litigation

on behalf of shareholders in state and federal courts throughout the
United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com